SeeThruEquity Research initiated coverage on Australia-based biotechnology company Cynata Therapeutics (ASX: CYP) with a target price of A$1.55.
For the full-year 2016 the broker expects revenue of A$5 million ($3.6 million) with pretax profit of A$1.6 million. Outlook for net income stands at A$1.6 million with earnings per share of A$0.02.
Headquartered in Melbourne, Cynata is engaged in developing a therapeutic stem cell platform. The company does not have any products in the market so far.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze